Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

UBT251 is a long-acting synthetic peptide triple agonist targeting the receptors for GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent ... UBT251 is categorized as a Class 1 innovative drug in ...

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently licensed for the treatment ... A survey of the US Food and Drug Administration Adverse Event Reporting System over 66 085 patients aged ...

pennmedicine.upenn.edu Background/aims Glucagon-like peptide-1 receptor (GLP-1R ... cohort of patients who initiated a new GLP-1R agonist was 1:3 age, gender, race, classes of active diabetes ...

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

ABSTRACT: The increasing use of glucagon-like peptide-1 (GLP-1) receptor agonists, including semaglutide ... offering new insights into the broader effects of these medications.

Pfizer to discontinue development of danuglipron, an oral GLP- receptor agonist for chronic weight management: New York Wednesday, April 16, 2025, 13:00 Hrs [IST] Pfizer Inc. anno ...

A groundbreaking study published in the journal Current Neuropharmacology highlights a concerning potential link between Glucagon-like Peptide-1 (GLP1) receptor agonists-widely used in blockbuster ...

For the past few years, the buzz around drugs termed rather technically GLP-1 agonists has been deafening. That stands for glucagon-like peptide 1 receptor ...

Once-daily orforglipron was more effective than placebo and just as safe as injectable GLP-1s in patients with diabetes and ...